As of November 10, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Psyence Biomedical Ltd. The largest reported stake is Psyence Labs Ltd.'s, at 49.75%. 7 filings are on record since December 10, 2025 (Schedule 13D/A, October 15, 2026).
Sell to companies like Psyence Biomedical Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Psyence Labs Ltd. · Sole voting: 2,643,659 · Shared voting: 0 · Sole dispositive: 2,643,659 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-15
- · Reporting person: AdvisorShares Trust · Sole voting: 258,538 · Shared voting: 0 · Sole dispositive: 258,538 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-05
- · Reporting person: Weiner Jeffrey David · Sole voting: 59,750 · Shared voting: 0 · Sole dispositive: 59,750 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-06-10
- · Holder: Psyence Labs Ltd. · Percent: 30.05% · SCHEDULE 13D
- · Holder: Weiner Jeffrey David · Percent: 5.07% · SCHEDULE 13G
Psyence Biomedical Ltd. has 7 Schedule 13D or 13G filings on record since 2025-12-10. 2 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Psyence Labs Ltd. | 49.75% | 2,643,659 | SCHEDULE 13D/A, 2026-10-15 | 2026-10-01 |
| AdvisorShares Trust | 6.78% | 258,538 | SCHEDULE 13G, 2026-10-05 | 2026-09-30 |
| KAOS Capital Ltd. | 4.91% | 313,876 | SCHEDULE 13D/A, 2026-01-13 | 2026-01-08 |
| 2.61% | 59,750 | SCHEDULE 13G/A, 2026-06-10 | 2026-02-25 |
Holding shares or following this stake? See who's behind Psyence Biomedical Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Psyence Biomedical Ltd. and the records around it.
Psyence Biomedical Ltd. elsewhere on the record
Companies that share a holder
- AdvisorShares Trust also filed stake reports on 8 other companies: Neuphoria Therapeutics Inc. (Oct 2026), Silo Pharma, Inc. (Jul 2026), Enveric Biosciences, Inc. (Jan 2026)
Watch Psyence Biomedical Ltd.
Get an email when Psyence Biomedical Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Psyence Biomedical Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Psyence Biomedical Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Psyence Biomedical Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Psyence Labs Ltd. | 2,643,659 | 0 | 2,643,659 | 0 | SCHEDULE 13D/A, 2026-10-15 |
| AdvisorShares Trust | 258,538 | 0 | 258,538 | 0 | SCHEDULE 13G, 2026-10-05 |
| Weiner Jeffrey David | 59,750 | 0 | 59,750 | 0 | SCHEDULE 13G/A, 2026-06-10 |
The latest filing identifies Psyence Biomedical Ltd. by CUSIP 74449F407 and gives its principal executive office as 121 Richmond Street West, Penthouse Suite 1300, Toronto (SCHEDULE 13D/A, 2026-10-15).
What the percentages are based on
2.61 - This percentage is based on 2,293,307 total outstanding shares reported by the company.Weiner Jeffrey David, SCHEDULE 13G/A, 2026-06-10
Source of funds (Item 3)
Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the following: On September 21, 2026, the Issuer, the Reporting Person and Psyence Biomed II Corp., an Ontario corporation and a wholly-owned subsidiary of the Issuer ("PBCII"), entered into a Share-for-Share Swap and Nomination Agreement (the "Swap Agreement"). On October 1, 2026, pursuant to the Swap Agreement, the Issuer issued 1,497,500 Common Shares (the "Additional Shares") to the Reporting Person at a deemed issue price of US$6.00 per Common Share, for aggregate non-cash consideration of US$8,985,000.Psyence Labs Ltd., SCHEDULE 13D/A, 2026-10-15
Purpose of Transaction (Item 4)
KAOS Capital Ltd.
The Reporting Persons believe the securities of the Issuer represent an attractive investment opportunity but have significant concerns about the current management of the Company's assets. The Reporting Persons intend to communicate with the Issuer's management and Board about a broad range of operational, management, corporate and strategic matters including corporate governance and strategic alternatives, and may communicate with other shareholders or third-parties about such matters. In particular, the Reporting Persons believe that the Issuer would benefit from the addition of alternative directors and a change in strategy. The Reporting Persons may also take other actions to influence the Issuer's management or policies. The Reporting Persons intend to continue to review their investment in the Issuer on a continuing basis, and depending upon various factors, including without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor (i) to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer, including through transactions involving the shares Common Stock and/or other equity, debt, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-13; the filing has the rest
Psyence Labs Ltd.
Item 4 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person acquired the Subject Shares pursuant to the exercise of an irrevocable put option granted to the Reporting Person under the Put Option Agreement, as previously disclosed in the Original Schedule 13D, and acquired the Additional Shares pursuant to the Swap Agreement, as described in Item 3 above. The Swap Agreement forms part of a broader strategic and commercial relationship between the Reporting Person and the Issuer. The Reporting Person acquired the Subject Shares and the Additional Shares for investment purposes. As a result of the issuance of the Additional Shares, the Reporting Person beneficially owns approximately 49.75% of the issued and outstanding Common Shares, and may be deemed to be an affiliate and control person of the Issuer. Standstill Restrictions. Pursuant to clause 5 of the Swap Agreement, for so long as the Reporting Person (together with its affiliates) beneficially owns any shares in the capital of the Issuer (the "Restricted Period"), the Reporting Person has agreed that it shall not, and shall cause its representatives not to, directly or indirectly, alone or in concert with any other person: (i) acquire, offer or propose to acquire, or agree to acquire, beneficial ownership (as defined in Rule 13d-3 under the Act) of any securities of the Issuer or any of its subsidiaries, or any direct or indirect rights to acquire any such …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-10-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-10 | KAOS Capital Ltd. | 16.77% | SCHEDULE 13D |
| 2026-01-13 | KAOS Capital Ltd. | 4.91% | SCHEDULE 13D/A |
| 2026-02-19 | Weiner Jeffrey David | 5.07% | SCHEDULE 13G |
| 2026-06-03 | Psyence Labs Ltd. | 30.05% | SCHEDULE 13D |
| 2026-06-10 | Weiner Jeffrey David | 2.61% | SCHEDULE 13G/A |
| 2026-10-05 | AdvisorShares Trust | 6.78% | SCHEDULE 13G |
| 2026-10-15 | Psyence Labs Ltd. | 49.75% | SCHEDULE 13D/A |
Questions about who owns Psyence Biomedical Ltd.
Who owns Psyence Biomedical Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Psyence Biomedical Ltd.: Psyence Labs Ltd. (49.75%, Schedule 13D/A, filed 2026-10-15) and AdvisorShares Trust (6.78%, Schedule 13G, filed 2026-10-05).
Who are the largest shareholders of Psyence Biomedical Ltd.?
By the share each holder's latest filing reports, the largest holders of Psyence Biomedical Ltd. on this page are Psyence Labs Ltd. (49.75%) and AdvisorShares Trust (6.78%).
When did Psyence Labs Ltd. buy into Psyence Biomedical Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Psyence Labs Ltd. on this page is the Schedule 13D, filed 2026-06-03, reporting 30.05%; its latest, Schedule 13D/A filed 2026-10-15, reports 49.75%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Psyence Biomedical Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 7, 2025 | Form D, private offering | $2M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Psyence Biomedical Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.